{"doi":"10.1016/j.blre.2012.11.001","title":"Mutational landscape of AML with normal cytogenetics: Biological and clinical implications","abstract":null,"journal":"Blood Reviews","year":2013,"id":637439,"datarank":0.6952093482344455,"base_score":4.634728988229636,"endowment":4.634728988229636,"self_citation_contribution":0.6952093482344455,"citation_network_contribution":0.0,"self_endowment_contribution":0.6952093482344455,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":102,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":376666,"name":"Paolo Sportoletti","orcid":"0000-0002-5630-9862","position":1,"is_corresponding":false},{"id":680021,"name":"Enrico Tiacci","orcid":"0000-0001-8055-0931","position":2,"is_corresponding":false},{"id":1655152,"name":"Massimo F. Martelli","orcid":null,"position":3,"is_corresponding":false},{"id":87416,"name":"Brunangelo Falini","orcid":"0000-0002-7198-5965","position":4,"is_corresponding":false},{"id":376677,"name":"Maria Paola Martelli","orcid":"0000-0001-9139-1729","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Mutational landscape of AML with normal cytogenetics: Biological and clinical implications","abstract":"Acute myeloid leukemia (AML) is a molecularly heterogeneous disease. Based on cytogenetics and FISH, AML patients are stratified into three major risk categories: favourable, intermediate and unfavourable. However, prognostic stratification and treatment decision for the intermediate risk category, that mostly comprises AML patients with normal cytogenetics (CN-AML), has been difficult due to the clinical heterogeneity and scarce knowledge of the molecular alterations underlying this large AML subgroup. During the past decade, the identification of several mutations associated with CN-AML has resulted into important advances in the AML field. In this review, we address the biological features of the main mutations associated with CN-AML and the impact of next generation sequencing studies in expanding our knowledge of the molecular landscape of CN-AML. In addition, we outline the prognostic value of mutations for risk stratification of CN-AML patients and discuss the potential of mutations discovery process for developing new molecular targeted therapies.","is_dataset_classified":null,"base_score":4.634728988229636,"endowment":4.634728988229636,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23261068","pmcid":null,"openalex_id":"https://openalex.org/W2026205985","authors":[],"funders":[],"total_grants":0,"fwci":4.1196,"citation_percentile":0.94949495,"influential_citations":0,"citation_trend":[{"year":2013,"count":3},{"year":2014,"count":8},{"year":2015,"count":14},{"year":2016,"count":13},{"year":2017,"count":12},{"year":2018,"count":6},{"year":2019,"count":6},{"year":2020,"count":10},{"year":2021,"count":7},{"year":2022,"count":6},{"year":2023,"count":8},{"year":2024,"count":3},{"year":2025,"count":5},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0268960X12000732?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0268960X12000732?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.blre.2012.11.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23261068","host_type":"repository"}],"fields_of_study":["Acute Myeloid Leukemia Research","Cancer Genomics and Diagnostics","Myeloproliferative Neoplasms: Diagnosis and Treatment","Biomarkers, Tumor","CCAAT-Enhancer-Binding Proteins","Cytogenetic Analysis","Gene Expression Regulation, Leukemic","Genetic Heterogeneity","High-Throughput Nucleotide Sequencing","Humans","Isocitrate Dehydrogenase","Isoenzymes","Leukemia, Myeloid, Acute","Mutation","Nuclear Proteins","Nucleophosmin","Prognosis","Risk Assessment","fms-Like Tyrosine Kinase 3"],"mesh_terms":["Nucleophosmin","Humans","Isocitrate Dehydrogenase","Isoenzymes","Mutation","Nuclear Proteins","Prognosis","Biomarkers, Tumor","Leukemia, Myeloid, Acute","Gene Expression Regulation, Leukemic","Risk Assessment","Genetic Heterogeneity","Cytogenetic Analysis","CCAAT-Enhancer-Binding Proteins","fms-Like Tyrosine Kinase 3","High-Throughput Nucleotide Sequencing"],"keywords":["Cytogenetics","Myeloid leukemia","Risk stratification","Oncology","Disease","Molecular genetics","Leukemia","Molecular cytogenetics","Internal medicine","Biology","Bioinformatics","Medicine","Genetics","Gene","Chromosome"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:57:07.164431Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}